127 related articles for article (PubMed ID: 35802985)
21. Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter.
Zhang H; Huang R; Pillarsetty N; Thorek DL; Vaidyanathan G; Serganova I; Blasberg RG; Lewis JS
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):322-32. PubMed ID: 24173571
[TBL] [Abstract][Full Text] [Related]
22. Radiation quality-dependent bystander effects elicited by targeted radionuclides.
Boyd M; Sorensen A; McCluskey AG; Mairs RJ
J Pharm Pharmacol; 2008 Aug; 60(8):951-8. PubMed ID: 18644188
[TBL] [Abstract][Full Text] [Related]
23. Radiolabeled (4-Fluoro-3-Iodobenzyl)Guanidine Improves Imaging and Targeted Radionuclide Therapy of Norepinephrine Transporter-Expressing Tumors.
Yamaguchi A; Hanaoka H; Higuchi T; Tsushima Y
J Nucl Med; 2018 May; 59(5):815-821. PubMed ID: 29217738
[No Abstract] [Full Text] [Related]
24. Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
Batra V; Samanta M; Makvandi M; Groff D; Martorano P; Elias J; Ranieri P; Tsang M; Hou C; Li Y; Pawel B; Martinez D; Vaidyanathan G; Carlin S; Pryma DA; Maris JM
Clin Cancer Res; 2022 Sep; 28(18):4146-4157. PubMed ID: 35861867
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of pharmacokinetics, safety, and efficacy of [211At] meta-astatobenzylguanidine ([211At] MABG) in patients with pheochromocytoma or paraganglioma (PPGL): A study protocol.
Kobayakawa M; Shiga T; Takahashi K; Sugawara S; Nomura K; Hanada K; Ishizuka N; Ito H
PLoS One; 2024; 19(5):e0303623. PubMed ID: 38805424
[TBL] [Abstract][Full Text] [Related]
26. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.
More SS; Itsara M; Yang X; Geier EG; Tadano MK; Seo Y; Vanbrocklin HF; Weiss WA; Mueller S; Haas-Kogan DA; Dubois SG; Matthay KK; Giacomini KM
Clin Cancer Res; 2011 Apr; 17(8):2339-49. PubMed ID: 21421857
[TBL] [Abstract][Full Text] [Related]
27. Extragranular storage of the neuron blocking agent meta-iodobenzylguanidine (MIBG) in human neuroblastoma cells.
Smets LA; Janssen M; Metwally E; Loesberg C
Biochem Pharmacol; 1990 Jun; 39(12):1959-64. PubMed ID: 2353937
[TBL] [Abstract][Full Text] [Related]
28. A case of (123)I-MIBG scintigram-negative functioning pheochromocytoma: immunohistochemical and molecular analysis with review of literature.
Kurisaki-Arakawa A; Saito T; Takahashi M; Mitani K; Yao T
Int J Clin Exp Pathol; 2014; 7(7):4438-47. PubMed ID: 25120831
[TBL] [Abstract][Full Text] [Related]
29. Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats.
Kiyono Y; Iida Y; Kawashima H; Ogawa M; Tamaki N; Nishimura H; Saji H
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):999-1005. PubMed ID: 12173012
[TBL] [Abstract][Full Text] [Related]
30. Manual on the proper use of meta-[
Ukon N; Higashi T; Hosono M; Kinuya S; Yamada T; Yanagida S; Namba M; Nakamura Y
Ann Nucl Med; 2022 Aug; 36(8):695-709. PubMed ID: 35794455
[TBL] [Abstract][Full Text] [Related]
31. Spatial Inhomogeneity of Cardiac Norepinephrine Transport Protein and Meta-[
Kusmic C; Giorgetti A; Barsanti C; Burchielli S; Petroni D; Kusch A; Genovesi D; Menichetti L; Marzullo P
Mol Imaging Biol; 2019 Jun; 21(3):482-490. PubMed ID: 30187232
[TBL] [Abstract][Full Text] [Related]
32. Regional alterations of myocardial norepinephrine transporter density in streptozotocin-induced diabetic rats: implications for heterogeneous cardiac accumulation of MIBG in diabetes.
Kiyono Y; Iida Y; Kawashima H; Tamaki N; Nishimura H; Saji H
Eur J Nucl Med; 2001 Jul; 28(7):894-9. PubMed ID: 11504086
[TBL] [Abstract][Full Text] [Related]
33. 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation.
Vaidyanathan G; Zalutsky MR
Bioconjug Chem; 1992; 3(6):499-503. PubMed ID: 1463779
[TBL] [Abstract][Full Text] [Related]
34. Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations.
Batra V; Makvandi M; Zuppa AF; Patel N; Elias J; Pryma DA; Maris JM
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27654664
[TBL] [Abstract][Full Text] [Related]
35. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.
Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E
Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195
[TBL] [Abstract][Full Text] [Related]
36. Effects of anesthetic agents on cellular 123I-MIBG transport and in vivo 123I-MIBG biodistribution.
Ko BH; Paik JY; Jung KH; Bae JS; Lee EJ; Choe YS; Kim BT; Lee KH
Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):554-61. PubMed ID: 17934728
[TBL] [Abstract][Full Text] [Related]
37. Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.
Strickland DK; Vaidyanathan G; Friedman HS; Zalutsky MR
J Neurooncol; 1995; 25(1):9-17. PubMed ID: 8523094
[TBL] [Abstract][Full Text] [Related]
38. Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.
Streby KA; Shah N; Ranalli MA; Kunkler A; Cripe TP
Pediatr Blood Cancer; 2015 Jan; 62(1):5-11. PubMed ID: 25175627
[TBL] [Abstract][Full Text] [Related]
39. Human dosimetry of free
Ukon N; Zhao S; Washiyama K; Oriuchi N; Tan C; Shimoyama S; Aoki M; Kubo H; Takahashi K; Ito H
EJNMMI Phys; 2020 Sep; 7(1):58. PubMed ID: 32960387
[TBL] [Abstract][Full Text] [Related]
40. Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters.
Kölby L; Bernhardt P; Levin-Jakobsen AM; Johanson V; Wängberg B; Ahlman H; Forssell-Aronsson E; Nilsson O
Br J Cancer; 2003 Oct; 89(7):1383-8. PubMed ID: 14520475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
